KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest & Investment Income: 2019-2025

Historic Interest & Investment Income for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $6.9 million.

  • Royalty Pharma's Interest & Investment Income fell 60.57% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year decrease of 20.64%. This contributed to the annual value of $47.3 million for FY2024, which is 34.51% down from last year.
  • Royalty Pharma's Interest & Investment Income amounted to $6.9 million in Q3 2025, which was down 17.10% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Interest & Investment Income registered a high of $43.9 million during Q4 2022, and its lowest value of $6.5 million during Q4 2023.
  • Its 3-year average for Interest & Investment Income is $13.3 million, with a median of $11.3 million in 2025.
  • Per our database at Business Quant, Royalty Pharma's Interest & Investment Income surged by 672.59% in 2021 and then crashed by 85.18% in 2023.
  • Over the past 5 years, Royalty Pharma's Interest & Investment Income (Quarterly) stood at $10.6 million in 2021, then spiked by 312.19% to $43.9 million in 2022, then slumped by 85.18% to $6.5 million in 2023, then spiked by 39.03% to $9.0 million in 2024, then crashed by 60.57% to $6.9 million in 2025.
  • Its Interest & Investment Income was $6.9 million in Q3 2025, compared to $8.3 million in Q2 2025 and $11.3 million in Q1 2025.